SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 10th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 4, 2017, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTUREImmune Pharmaceuticals Inc • May 10th, 2017 • Pharmaceutical preparations • New York
THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 430 East 29th Street, Suite 940, New York, New York 10016, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
